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Abstract
Smad proteins are classified in different groups based on their functions in mediating transforming growth factor b
(TGFb) superfamily components. Smad1/5/8 mainly mediate bone morphogenetic proteins (BMP) pathway and
Smad2/3 mainly mediate TGFb pathway. Smad4 functions as common Smad to mediate both pathways. Previous
studies showed many members of TGFb superfamily play a role in carcinogenesis. The current review focuses on
the role of TGFb signaling Smads in squamous cell carcinomas (SCCs). TGFb signaling inhibits early tumor
development, but promotes tumor progression in the late stage. Although Smad2, Smad3 and Smad4 are all TGFb
signaling Smads, they play different roles in SCCs. Genetically, Smad2 and Smad4 are frequently mutated or
deleted in certain human cancers whereas Smad3 mutation or deletion is infrequent. Genetically engineered
mouse models with these individual Smad deletions have provided important tools to identify their diversified
roles in cancer. Using these models, we have shown that Smad4 functions as a potent tumor suppressor and its
loss causes spontaneous SCCs development; Smad2 functions as a tumor suppressor and its loss promotes SCC
formation initiated by other genetic insults but is insufficient to initiate tumor formation. In contrast, Smad3
primarily mediates TGFb-induced inflammation. The functions of each Smad also depends on the presence/
absence of its Smad partner, thus need to be interpreted in a context-specific manner.
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TGFb/Smad signaling
The transforming growth factor b (TGFb) signaling
pathway has been implicated in the regulation of var-
ious biological processes including embryonic develop-
ment, fibrosis, tumor development, immunity
regulation and wound healing. Function of the TGFb
signaling pathway depends on the binding of ligands to
cell membrane receptors, activating cytoplasm media-
tors into the nucleus, and regulating expression of
their target gene. The ligands of the immediate TGFb
family include 3 isoforms (TGFb 1, 2, 3). Cell-surface
receptors of TGFb signaling are mainly classified into
two subtypes: type I (TGFbRI) and type II (TGFbRII).
Smad-dependent TGFb signaling from cytoplasm to
nucleus are primarily three Smad isoforms in the
Smad family, i.e., Smad2, 3, and 4. The binding of
ligands to TGFbRII leads TGFbRI to phosphorylate
Smad2 and Smad3, which then bind to Smad4 forming
at r i m e r i cc o m p l e xa n dt r a n s locate into the nucleus. In
the nucleus, the Smad trimeric complex binds the
Smad binding element (SBE) of target genes, regulating
expression of TGFb response genes directly or through
recruiting other co-factors (co-activators or co-repres-
sors) to target genes [1,2] (Figure 1).
The TGFb signaling pathway has been reported to
play either a suppressive or a promotive role in cancer
development depending on tumor stage and type [3,4].
Evidence for the suppressive role of TGFb signaling in
cancer includes genomic deletion/mutation with sev-
eral core components of TGFb signaling identified in
human cancers [5,6] and TGFb mediated cell growth
inhibition and apoptosis. However, TGFb induces
angiogenesis, inflammation and epithelial-mesenchymal
transition (EMT) providing a beneficial environment
for tumor progression and metastasis. The current
review will focus on recent progress elucidating the
role of TGFb signaling Smads in squamous cell carci-
noma (SCC).
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Aberrant Smad2 in human cancer
Smad2 maps to the 18q21 chromosome, near the Smad4
locus in the human genome [7]. Mutation analysis identi-
fied 6% colon cancers with missense mutations in MH2 or
MH1 of Smad2. Biochemical and functional analysis indi-
cated these mutations were loss of functional mutations
[7]. Subsequent studies have shown mutations of Smad2
in lung cancer and hepatocellular carcinoma [8,9]. In SCC,
Smad2 point mutation is infrequent in human head and
neck SCC (HNSCC) [10-12] with only one report of a
Smad2 mutant HNSCC cell line [13]. However, we have
found about 67% of poorly differentiated human skin
SCCs have loss of heterozygosity (LOH) at the Smad2
locus [14]. By immunostaining, 70% human skin SCC
show Smad2 protein reduction/loss in tumor tissues, espe-
cially, the incidence of Smad2 loss is higher in poorly dif-
ferentiated SCCs [14]. In addition, loss or reduction of
Smad2 expression has been shown in other human SCCs
including genital SCC, oral SCC and cervical SCC [15-18].
Smad2 loss is not a tumor initiating event but promotes
skin carcinogenesis in vivo
Germline Smad2 deletion in mice causes embryonic
lethality [19-22]; heterozygous Smad2 mice are viable,
fertile, and no spontaneous tumors develope in their
lifespan. Specific targeted Smad2 disruption to hepato-
cytes does not affect the liver development, however
hepatocyte-specific Smad2 deletion increases CCL4-
induced hepatocyte proliferation and spontaneous
acquired EMT in vitro [23]. In Smad2/APC (adenoma-
tous polyposis coli) double heterozygous mice, Smad2
deletion accelerates APC mutation-induced intestinal
tumor growth and invasion but does not increase the
number of tumors [24]. Smad2 heterozygous mice
(Smad2+/-) do not develop spontaneous cancer in any
tissues. However, when Smad2+/- mice were exposed to
a two-stage chemical carcinogenesis protocol, they
developed a greater number of less-differentiated tumors
with locally invasive and EMT in comparison with wild
type control mice [25]. To fully understand the in vivo
role of Smad2 in skin carcinogenesis, we have estab-
lished Smad2 conditional knockout mice that targeted
Smad2 deletion to epithelial cells using the keratin 5
(K5) promoter, in which keratinocyte-specific Smad2
deletion in homozygous (K5.Smad2-/-) or heterozygous
(K5.Smad2+/-) mice can be induced by RU486 [14]. K5.
Smad2-/- mice do not develop spontaneous skin tumors,
but have accelerated tumor formation and malignant
conversion in a two-stage chemical carcinogenesis
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Figure 1 Schematic of Smads mediated TGFb signaling pathway. TGFb ligand binds to TGFbRII/TGFbRI receptors leading to phosphorylation
of Smad2/3. Phosphorylated Smad2/3 binds to Smad4 to form a protein complex that undergoes nuclear translocation and regulates the
expression of TGFb target genes through binding to the Smad-binding element (SBE).
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entiated, exhibited increased EMT and angiogenesis.
These results indicate Smad2 deletion in the skin is not
a tumor initiating event, but Smad2-deficient epidermis
is more susceptible to skin tumor formation and malig-
nant conversion.
Smad2 loss induced EMT and angiogenesis through
upregulation of Snail and HGF
TGFb is well documented as an inducer of EMT [26]
and a potent stimulator of angiogenesis [27], however,
neither TGFb nor its target VEGF, which are usually
elevated in tumor cells and contribute to angiogenesis
and tumor metastasis [28,29], is increased in K5.
Smad2-/- SCC [30]. Furthermore, K5.Smad2-/- tumors
do not have increased levels of Smad-independent
TGFb signaling factors related to EMT, i.e., pJNK,
pERK, and pMAPK. Further analyses revealed that
expression of Snail, a TGFb target gene functioning as a
transcriptional repressor of E-cadherin [31], was acti-
vated by increased Smad4 binding to SBE of the Snail
promoter in K5.Smad2-/- skin [14]. At the transcrip-
tional level, Smad3 usually directly binds to the SBE of a
target gene, and subsequently recruits Smad4 to the
same SBE. Smad2 does not bind to DNA directly but
complexes with Smad3 and Smad4 as either a co-activa-
tor or a co-repressor for Smad3 and Smad4 [32]. There-
fore, loss of Smad2 binding to Snail’sS B Ei n c r e a s e s
Snail expression dependent on recruitment of Smad4 to
Snail’s SBE through Smad3; this process contributes to
EMT. Similarly, Smad3 and Smad4 over Smad2 in med-
iating EMT have also been observed in other cell types
[23,26,33,34].
With respect to Smad2 loss-associated angiogenesis,
we have found that K5.Smad2-/- tissue expresses higher
levels of hepatocyte growth factor (HGF) that activates
its receptor c-Met in endothelial cells [30]. HGF is an
independent, potent angiogenic factor via stimulation of
endothelial cell growth, migration, scatter, and elonga-
tion which favors formation of a microenvironment ben-
eficial for tumor development and invasion [35,36]. In
keratinocytes, Smad-2, -3, and -4 all bind to SBE of the
HGF promoter [30]. However, Smad2 recruits co-repres-
sors including TGIF and HDAC to the SBE site, but
Smad4 mainly recruits co-activators CBP/p300. Smad2
deletion in keratinocytes dramatically increased the
binding of Smad4/CBP/p300 complex to the SBE site of
the HGF promoter and resulted in overexpression of
HGF. Consistent with our biochemical analyses, human
SCCs from the skin or head and neck, Smad2-negative
tumors have higher HGF expression; however, once
Smad3 and Smad4 are lost, HGF expression is also
abrogated [30]. Furthermore, short term of treatment
with a c-Met inhibitor significantly reduced Smad2 loss-
associated angiogenesis [30], showing a potential appli-
cation of c-Met inhibitor in treating human SCC with
Smad2 loss.
The role of Smad3 in SCC
Aberrant Smad3 in human cancer
Smad3 is located in 15q21-q22 of human chromosome.
Recent publications indicate Smad3 mutations are asso-
ciated with familial thoracic aortic aneurysms and dis-
sections [37,38]. Smad3 mutation has been identified in
one colorectal cancer cell line [39], and is infrequent in
human colon cancer tissues and breast cancers [40-42].
Smad3 missense mutation was identified in HNSCC at a
very low frequency, but it remains to be determined if
this is a driver mutation [43]. In human cancers, the
loss of Smad3 expression has been associated with var-
ious malignant carcinomas and is recognized as a tumor
suppressor [44-46]. However, Smad3 protein loss is not
common in skin SCC [14] and increased Smad3 expres-
sion has been reported in breast cancer [41].
Tumor suppressive effects of Smad3
In hematopoiesis, Smad3 plays a major role in TGFb-
mediated growth inhibition [47]. In order to define the
role of Smad3 in tumorigenesis, Smad3 deletion or over-
expression has been investigated in vitro and in vivo.
Smad3-/- keratinocytes derived from Smad3-/- neonates
and transduced with v-ras
Ha demonstrated reduction of
TGFb induced cell growth arrest and induction of kera-
tin 8, a marker of simple epithelia and malignant con-
version of squamous cell carcinomas. When grafted
onto nude mice, v-ras
Ha-transduced Smad3-/- keratino-
cytes developed papilloma and progressed to SCC, but
v-ras
Ha-transduced Smad3+/+ keratinocytes only formed
papillomas [48,49]. The studies suggest Smad3 does not
alter proliferation, but prevents malignant conversion of
papillomas formed by engraftment onto nude mice.
Similarly, when Smad3 is introduced into SNU-484
human gastric cancer cells (Smad3 deficient), they
recover TGFb sensitivity, reduced tumorigenicity and
enhanced expression of the tumor suppressor E-cad-
herin [45]. In liver-specific Smad3 transgenic mice, ecto-
pic expression of Smad3 reduces liver susceptibility to
chemically induced-hepatocellular carcinoma through
the mechanism of promoting hepatocyte apoptosis by
repressing Bcl-2 transcription, suggesting a tumor sup-
pressive role for Smad3 in mouse liver carcinogenesis
[50]. Those studies indicated Smad3 has tumor suppres-
sive effects mainly through Smad3-mediated TGFb
function.
Tumor promotion effects of Smad3
In three Smad3 knockout mouse models from different
laboratories, only one has been reported to develop
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the tumor development is related to a helicobacter
infection [51-54]. The Smad3+/- and Smad3-/- mice do
not develop spontaneous skint u m o r s .I n t e r e s t i n g l y ,i n
the two-stage skin carcinogenesis experiment, both
Smad3-/- and Smad3+/- mice are resistant to SCC for-
mation, compared to wild-type mice [55]. Smad3 tumors
show reduced cell proliferation and inflammation but
increased apoptosis [55]. TGFb overexpression and sub-
sequent inflammation induc e db yT P Ag r e a t l yc o n t r i -
bute to cancer development [56]. Therefore, one
explanation for the observed resistance to chemically
induced skin carcinogenesis in Smad3-/- mice may be
attributed to Smad3 deletion-mediated blocking of
TGFb signaling, evidenced by reduction of TGFb-
induced activator protein-1 family members and TGFa
observed in TPA treated Smad3-/- cells and tissue.
Similar to our findings, another group also reported
Smad3+/- mice develop fewer tumors than the wild-type
mice during chemically induced skin carcinogenesis [25].
Thus, in vivo r o l eo fS m a d 3i ns k i nc a r c i n o g e n e s i si s
complicated and may be influenced by microenviron-
ment and tissue types. As a major mediator of the
TGFb signaling pathway, Smad3 may be either a tumor
suppressor or promoter in a context dependent manner.
The role of Smad4 in SCC
Aberrant Smad4 in human cancer
Smad4 was originally identified as a tumor suppressor in
pancreatic cancer [57] and later characterized as a key
mediator of TGFb signaling [58]. Genetically, homozy-
gous deletion of Smad4 has been identified in pancreatic
cancer and colorectal adenocarcinomas [57,59]; germline
mutation of Smad4 causes Juvenile Polyposis Syndrome
(JPS) [60]. In addition, intragenic mutation and loss of
heterozygosity (LOH) at the Smad4 locus has been
reported in many tumors, although these genetic altera-
tions may not directly cause inactivation of Smad4 in
some cancers [61-63]. Recent genome wide analysis of
HNSCC show frequent deletion of the 18q region where
Smad4 is located [43], and heterozygous loss of Smad4
is presented in HNSCC [64]. At the protein and tran-
scriptional level, Smad4 loss and reduction has been
found in SCCs from different tissues. In human esopha-
geal SCC, 51.2% ~ 67.8% patients showed Smad4 loss or
reduction and Smad4 loss is associated with invasion of
esophageal SCC [65,66]. 61.12% oral squamous cell car-
cinoma (OSCC) exhibited Smad4 loss [67]. We exam-
ined Smad4 mRNA expression in human HNSCC, and
found 86% of tumors and 67% of adjacent non-malig-
nant mucosa had > 50% Smad4 reduction. Smad4 pro-
tein staining is consistent with mRNA level. In contrast
to the strong Smad4 staining in normal mucosa, Smad4
is reduced or lost in HNSCC and adjacent non-tumor
tissues. These findings suggest that Smad4 down regula-
tion is an early event in HNSCC development [63]. In
addition, we found LOH at the Smad4 locus in 33% of
HNSCCs, indicating genetic defects and other factors,
such as epigenetic, posttranscriptional or posttransla-
tional modifications, cooperatively contribute to reduced
Smad4 expression in HNSCC [63]
Smad4 loss in epithelial cells causes spontaneous tumor
development in mice
Germline Smad4 knockout mice died in embryos
[68,69]. In order to study the role of Smad4 in cancer,
mouse models with Smad4 deletion specifically targeted
to certain tissue types have been used [63,70,71]. These
mice had a normal lifespan. MMTV-Cre mediated
Smad4 deletion results in spontaneous mammary gland
tumors and skin SCC [71]. Smad4 loss related tumori-
genesis is frequently accompanied by inactivation of
phosphatase and tensin homolog deleted on chromo-
some 10 (PTEN), activation of AKT, fast proliferation
and nuclear accumulation of cyclin D1 and decreased
P21 [71]. Keratinocyte-specific Smad4 deletion mediated
by K5.Cre further confirmed Smad4 loss interrupted the
development of hair follicles and caused spontaneous
skin SCC [70]. Smad4/PTEN double knockout mice had
accelerated skin tumor formation in comparison with
MMTV-Cre or K5-Cre driven Smad4 deletion mice
[70,71]. When Smad4 and PTEN genes were simulta-
neously deleted in epithelial cells of the upper digestive
tract in Smad4/PTEN double knockout mice, mice
rapidly developed forestomach tumors and were mori-
bund within 3 months due to difficulties with food
ingestion. The studies suggest Smad4 and PTEN act
synergistically to regulate epidermal proliferation and
differentiation [70,72]. To understand the role of Smad4
loss in head and neck carcinogenesis, we selectively
induced Smad4 deletion in oral epithelia. Similar to
spontaneous tumor formation in Smad4-deleted skin
and mammary glands [70,71,73], Smad4 loss in head
and neck tissues (HN-Smad4-/-) also developed sponta-
neous HNSCC [63]. Although mice with heterozygous
Smad4 deletion (HN-Smad4+/-) do not develop sponta-
neous HNSCC, they rapidly develop HNSCC (within 3
months) in the presence of a Kras
12D mutation [63].
This indicates that haploid insufficiency of Smad4, con-
ferring a 50% of Smad4 protein reduction [68,69], could
be sufficient to promote tumor formation. Interestingly,
Samd4 loss in head and neck epithelia caused down reg-
ulation of Fanc/Brca pathway genes. This finding is
intriguing because mutations of Fanc/Brca genes in Fan-
coni Anemia patients predispose these patients to
HNSCC [74]. Different from K5.Smad2-/- mice, Smad4
deletion caused increased TGFb expression and asso-
ciated inflammation and angiogenesis [63,75]. In Smad4
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increased and Smad3 deletion abrogates Smad4 loss-
associated inflammation. Thus, inflammation in Smad4
deleted SCCs appears to be due to Smad3-dependent
TGFb signaling [63]. Similarly, angiogenesis in Smad4
deleted SCCs is also associated with increased TGFb1,
which induces angiogenesis directly through activation
of Smad1/5 in endothelial cells and through activation
of VEGF [75]. Consistent with the finding that Smad4 is
required for TGFb-mediated EMT, Smad4-/- SCCs do
not undergo EMT at early stage [14], yet they are able
to metastasize [63]. A similar finding was also reported
in Smad4 deletion-associated pancreatic cancer [76].
Thus, Smad4 loss-induced metastasis appears to be
independent of EMT.
Conclusion
TGFb signaling Smads play different roles in the regula-
tion of tumor development and promotion. Gene dele-
tion and mutation of Smad4 and Smad2 have been
identified in certain human cancers and implicated in
cancer development. Carcinogenesis studies based on a
genetically engineered mouse model with deletion of
signaling Smads in epithelia provide fundamental infor-
mation for the role of individual Smads in SCC initia-
tion and promotion. The roles and mechanisms of
signaling Smads in SCC found in our studies are sum-
marized in Figure 2. Genetic deletion of Smad4 in
epithelia of a mouse model resulted in spontaneous skin
SCC and HNSCC development. Further analysis
demonstrated Smad4 loss is associated with inactivation
of PTEN and p21, down regulation of Fanc/Brca path-
way genes and upregulation of TGFb expression.
Reduced Fanc/Brca pathway genes directly caused DNA
damage which is associated with tumor initiation. Inac-
tivation of PTEN and p21 promote cell proliferation
and inhibit cell apoptosis, and cooperate with TGFb-
induced inflammation to accelerate tumor development
and progression. Smad2 deletion in epidermal keratino-
cytes does not initiate tumorigenesis, but accelerates
skin tumor development and malignant cancer transi-
tion. Smad2 loss transcriptionally upregulates snail and
HGF through recruiting Smad3 and Smad4 binding to
the SBE site of snail and HGF. Overexpression of Snail
Smad2 loss 
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Figure 2 Schematic summarizing the role of signaling Smads in epithelial carcinogenesis. Smad2 loss in epithelia upregulates Snail and
HGF expression through increasing Smad4 to the SBE of target genes recruited by Smad3. Upregulation of Snail and HGF resulted in epithelial
cells undergoing EMT and increasing stromal angiogenesis respectively, which accelerates chemically induced SCC formation. Smad4 deletion in
epithelia downregulates Fanc/Brca genes, inactivates PTEN and p21, and increases TGFb expression. Reduction in Fanc/Brca pathway genes
caused DNA damage and is an initiating factor for tumorigenesis. Inactivation of PTEN and p21 increase cell proliferation and inhibit cell
apoptosis, cooperating with TGFb-induced inflammation to promote SCC development and progression. Smad3 loss in skin inhibits TGFb
induced inflammation and exhibits resistance to chemical induced skin carcinogenesis.
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attributed to Smad2 deletion-induced tumorigenesis.
Smad3 gene mutation is infrequent in human carci-
noma. However, both repressive and promotive role in
carcinogenesis have been documented for Smad3, thus
Smad3 might play a dual role in tumor development
dependent on the context of tumor type and its effect
on tumor microenvironment. For instance, keratinocyte-
deficient Smad3 showed promotion effect on tumor for-
mation and malignant transition under an immune
compromised condition mainly due to the loss of TGFb
mediated cell growth and apoptosis inhibition, but
TGFb-induced inflammation plays a critical role in che-
mical induced skin carcinogenesis. As individual Smads
actively interact, it remains to be determined how loss
of more than one Smad gene affects SCC
carcinogenesis.
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